Nevertheless, when BRAF and KRAS mutations coexist with mutations of the tumour suppressor serine/threonine kinase 11 (STK11; also known as liver kinase B1, LKB1), cancer cells develop resistance to this dual inhibition, suggesting a new predictive biomarker to tailor combinatorial treatment.13 The gene discussed is STK11; the disease is cancer.